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Genetic and Epigenetic Interplay Within a COLGALT2 
Enhancer Associated With Osteoarthritis
Yulia S. Kehayova,1  Emily Watson,1 J. Mark Wilkinson,2  John Loughlin,1  and Sarah J. Rice1
Objective. The osteoarthritis (OA)– associated single- nucleotide polymorphism (SNP) rs11583641 is located in 
COLGALT2, encoding a posttranslational modifier of collagen. In cartilage, the SNP genotype correlates with DNA 
methylation in a putative enhancer. This study was undertaken to characterize the mechanistic relationship between 
rs11583641, the putative enhancer, and COLGALT2 expression using cartilage samples from human patients and a 
chondrocyte cell model.
Methods. Nucleic acids were extracted from articular cartilage samples obtained from patients with OA (n = 137). 
Samples were genotyped, and DNA methylation was quantified at 12 CpGs using pyrosequencing. The putative 
enhancer was deleted in Tc28a2 chondrocytes using clustered regularly interspaced short palindromic repeat/
Cas9, and the impact on nearby gene expression was determined using real- time quantitative polymerase chain 
reaction. Targeted modulation of the epigenome using catalytically dead Cas9 (dCas9) constructs fused to DNA 
methyltransferase 3a or ten–eleven translocase 1 allowed for the investigation of a causal relationship between DNA 
methylation and enhancer activity.
Results. The genotype at rs11583641 correlated with DNA methylation at 3 CpGs, and the presence of the 
OA risk allele, C, corresponded to reduced levels of methylation. Deletion of the enhancer resulted in a 2.7- fold 
reduction in COLGALT2 expression. Targeted methylation and demethylation of the CpGs had antagonistic effects 
on COLGALT2 expression. An allelic imbalance in the expression of COLGALT2 was identified in the cartilage from 
patients with OA, with relative overexpression of the OA risk allele. Allelic expression ratios correlated with DNA 
methylation at 4 CpGs.
Conclusion. COLGALT2 is a target of OA genetic risk at this locus. The genotype at rs11583641 impacts DNA 
methylation in a gene enhancer, which, in turn, modulates COLGALT2 expression. COLGALT2 encodes an enzyme 
that initiates posttranslational glycosylation of collagens and is therefore a compelling OA susceptibility target.
INTRODUCTION
Osteoarthritis (OA) is a multifactorial musculoskeletal condi-
tion that most commonly affects the hips, knees, and base of the 
thumbs (1). The disease is characterized by focal thinning and loss 
of articular cartilage, which leads to pain and stiffness in the affected 
joint. This results in reduced mobility and comorbidities, such as 
cardiovascular disease, ultimately leading to an increase in the rate 
of all- cause mortality (2,3). Current treatments are limited to symp-
tomatic pain relief and physical therapy, and surgical interventions 
involving joint replacement are common in end- stage disease.
Genetic predisposition accounts for >50% of total OA sus-
ceptibility (4). Approximately 90 independent genetic loci have 
been significantly associated with OA, according to the findings 
of genome- wide association studies (GWAS) (5–15). Risk loci 
are marked by single- nucleotide polymorphisms (SNPs), of which 
the majority reside within noncoding regions of the genome. Func-
tional SNPs are thought to contribute to OA pathogenesis by 
altering the expression of target genes, disrupting cartilage home-
ostasis. Due to the genetic complexity of the reported regions, the 
identification of functional SNPs and effector genes at the majority 
of OA risk loci remains elusive (16,17). In recent years, post- GWAS 
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integration of epigenetic data sets has increasingly been con-
ducted to colocalize genetic risk loci with changes to the carti-
lage epigenome (18– 21). Correlations between genotypes at OA 
association SNPs and DNA methylation have been identified in 
cartilage, marking methylation quantitative trait loci (QTLs) (19– 22). 
Identification of methylation QTLs prioritizes SNPs, genes, and reg-
ulatory elements for downstream analysis and provides insight into 
the potential molecular mechanisms through which risk variants 
influence disease susceptibility (23).
A GWAS using the UK Biobank data set identified the SNP 
rs11583641 at chromosome 1q25.3 to be significantly associated 
with hip OA (P = 5.6 × 10– 10) (11). Subsequently, a cartilage methy-
lome analysis revealed that rs11583641 acts as a methylation QTL 
(20). Presence of the major, and OA effect, allele of rs11583641 
was found to correlate with reduced DNA methylation at a sin-
gle intronic CpG (cg18131582) (20). Both the SNP and CpG 
are located in the gene body of COLGALT2. Furthermore, COL-
GALT2 expression was shown to be significantly increased in OA 
hip cartilage compared to non- OA cartilage (20). Based on these 
findings, the COLGALT2 gene and its putative regulatory element 
have been prioritized for further investigation.
COLGALT2 encodes the enzyme Colgalt2, which is one 
of two known galactosyltransferases (the other encoded by 
COLGALT1) that initiate collagen glycosylation, a posttransla-
tional modification (24). Glycosylation has been functionally linked 
to oligomerization and stabilization of the collagen triple helix 
(25,26). Collagen constitutes up to 60% of the dry weight of artic-
ular cartilage; therefore, anomalies in folding and stability could 
result in a loss of tissue integrity and breakdown of cartilage. This 
highlights COLGALT2 as a compelling target of the OA genetic 
risk at chromosome 1q25.3.
Few functional analyses of OA risk loci have successfully 
demonstrated causal relationships between the SNP genotype, 
DNA methylation, and the expression of target genes. In this 
study, we set out to test the prioritized region for enhancer activ-
ity, to identify the gene targets of the SNP and enhancer, and 
to investigate a functional effect of changes in DNA methylation 
associated with OA risk on gene expression.
PATIENTS AND METHODS
Cartilage samples and ethics approval. Cartilage sam-
ples were obtained from the joints of patients undergoing knee 
or hip replacement surgery due to primary OA or femoral neck 
fracture. The Newcastle and North Tyneside Research Ethics 
Committee granted ethics approval for sample collection. Verbal 
and written informed consent was obtained from each patient 
prior to surgery (Research Ethics Committee reference no. 14/
NE/1212). Nucleic acids were extracted from cartilage as previ-
ously described (27). Patient details can be found in Supplemen-
tary Table 1 (available on the Arthritis & Rheumatology website 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/ abstract).
Genotyping. Following polymerase chain reaction (PCR) 
amplification of the SNP region, samples were genotyped using 
a PyroMark Q24 system (Qiagen), according to the manufac-
turer’s instructions. Primer sequences were generated using 
PyroMark assay design software (Qiagen) and purchased from 
IDT (Supplementary Table 2, available on the Arthritis & Rheu-
matology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41738/ abstract).
Methylation quantification. Genomic DNA (500 ng) was 
treated with sodium bisulfite using EZ DNA Methylation Kits (Zymo 
Research). Assays were designed to capture the 12 investigated 
CpGs (PyroMark assay design software; Qiagen) (Supplemen-
tary Table 3, available on the Arthritis & Rheumatology website 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/ abstract). 
Bisulfite-treated DNA was amplified by PCR, and DNA methylation 
was quantified using a PyroMark Q24 system. Each measurement 
was performed in duplicate, and replicate values that differed by 
>5% were excluded from the analysis.
Allelic expression imbalance analysis. The relative ratio 
of C:T at rs11583641 was quantified using pyrosequencing in DNA 
and complementary DNA (cDNA) from heterozygous patients. 
Assay details can be found in Supplementary Table 2 (available on 
the Arthritis & Rheumatology website at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41738/ abstract). Cartilage samples were 
analyzed in triplicate. Replicate values with >5% differences were 
excluded. Allelic expression in cDNA was normalized to that in 
genomic DNA for each patient.
Reporter gene assay. The investigated region was 
cloned into the Lucia CpG- free promoter vector (InvivoGen). 
The putative enhancer was amplified from pooled genomic 
DNA samples using primers containing the required restriction 
enzyme sequences for downstream cloning (Supplementary 
Table 2, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/ abstract). 
The PCR product was first cloned into the pCR2.1- TOPO 
vector (ThermoFisher) and transformed into chemically com-
petent Escherichia coli (E coli). Colonies were grown over-
night, and extracted plasmid DNA was sequenced using the 
Sanger method (Source BioScience). Plasmids containing 
each of the 3 haplotypes for rs943409 and rs734657 were 
selected, and DNA was digested with Avr II and Spe I (New 
England Biolabs). The inserts were subcloned into a CpG- free– 
promoter vector containing a Lucia reporter gene (InvivoGen). 
Plasmids were methylated or mock- methylated in vitro using 
CpG Methyltransferase (New England Biolabs), which was 
confirmed using Hga I restriction digest (New England Bio-
labs). Tc28a2 cells, an immortalized human chondrocyte cell 
line, were seeded onto a 96- well plate (5,000 cells/well) and 
transfected with 100 ng of pCpG- free promoter and 10 ng of 
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pGL3- promoter (Promega) using Lipofectamine 2000 (Invitro-
gen). Cells were lysed after 24 hours. Luminescence was read 
and analyzed, as previously described (28).
Genome and epigenome modulation using Cas9. Two 
guide RNA (gRNA) sequences (gRNAs 1 and 2) were designed (using 
the IDT gRNA Design Tool) to target upstream and downstream of 
the CpGs (Supplementary Table 3, available on the Arthritis & Rheu-
matology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41738/ abstract). Sequences were ordered as single- stranded 
DNA oligonucleotides, annealed, and cloned into the PX462 Cas9 
plasmid, as previously described in detail (27). Constructs were 
nucleofected into Tc28a2 cells, and deletions were confirmed as 
previously described (27). Complementary DNA was synthesized 
from 1 µg of RNA in a reverse transcription reaction with Super-
Script II Reverse Transcriptase (Invitrogen). Gene expression 
was measured by real- time quantitative PCR (QuantStudio 3), using 
TaqMan primers and probes. The expression of target genes, rela-
tive to that of housekeeping genes 18S, GAPDH, and HPRT1, was 
calculated using the formula 2− Δ ct (28). The predesigned TaqMan 
assays used in this study were purchased from IDT (Supplementary 
Table 4, available on the Arthritis & Rheumatology website at http://
onlin elibr ary.wiley.com/doi/10.1002/art.41738/ abstract).
For epigenome modulation, 6 gRNAs targeting the region 
were designed as described above (Supplementary Table 3, 
available on the Arthritis & Rheumatology website at http://onlin e  
libr ary.wiley.com/doi/10.1002/art.41738/ abstract). For DNA meth-
yltransferase 3a (DNMT3a)- mediated methylation of the CpGs, the 
gRNA sequences were synthesized as single- stranded DNA oligo-
nucleotides, annealed, and ligated to the catalytically dead Cas9 
(dCas9)– DNMT3a– enhanced green fluorescent protein (EGFP) 
plasmid (Addgene plasmid 71666), as previously described (27). 
Plasmid DNA (5 µg) was nucleofected into Tc28a2 cells, and 
successful transfection was confirmed after 24 hours using GFP 
visualization (AxioVision; Zeiss). Supplementary Figure 1 contains 
representative images of Tc28a2 cells following transfection with 
dCas9- DNMT3a– EGFP plasmid (available on the Arthritis & Rheu-
matology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41738/ abstract).
For demethylation of the enhancer using dCas9–ten–eleven 
translocation 1 (TET1), Tc28a2 cells that had been previously stably 
integrated with a gene expressing an inducible dCas9- TET1 con-
struct were created and cultured as described by Parker et al (29). 
The 6 sequences targeting the enhancer (Supplementary Table 3, 
available on the Arthritis & Rheumatology website at http://onlin e  
libr ary.wiley.com/doi/10.1002/art.41738/ abstract) were ordered 
from IDT as gRNAs. The gRNAs and trans- activating CRISPR 
RNA (tracrRNA; IDT) were diluted to 100 µM with Duplex Buffer 
(IDT). Each gRNA was mixed with tracrRNA (1:1) in a 4 µl reaction. 
The gRNA and the tracrRNA were annealed at 95°C for 5 minutes 
and cooled to room temperature to form duplexes. The duplexes 
were then transfected into the Tc28a2/dCas9- TET1 cells 24 hours 
after fusion protein induction. The cells were grown in a standard 
culture medium containing doxycycline (2 μg/ml) for another 
48 hours, after which they were left to recover in an antibiotic- 
free medium for 24 hours.
For both experiments, cells were harvested 72 hours post-
transfection. DNA was extracted from harvested cell pellets using 
the PureLink Genomic DNA Mini kit (ThermoFisher), and RNA was 
extracted using a NucleoSpin TriPrep kit (Macherey- Nagel).
Statistical analysis. Genotype and methylation corre-
lations were calculated using the Kruskal- Wallis test. For Lucia 
reporter assays, we corrected for multiple comparisons using the 
Holm- Sidak or Dunn’s test. Changes in gene expression follow-
ing Cas9 modulation were calculated using paired t- tests. Allelic 
expression imbalance and DNA methylation relationships were 
determined using linear regression analysis. All tests were per-
formed in GraphPad Prism 8.3.1.
RESULTS
Investigation of OA-associated methylation QTLs. 
The region surrounding cg18131582, at which an OA methyl-
ation QTL has previously been identified, is a putative intronic 
enhancer, located 6 kb upstream of the association SNP, 
rs11583641 (Figure 1A). We have identified that cg18131582 
resides in a cluster of 8 CpGs spanning 433 bp (CpGs 3– 10) 
(Figure 1A). To determine the physical limits of the differen-
tially methylated region, we initially focused our attention on this 
cluster, along with the 4 most proximal CpGs flanking the region 
(CpG1– 2 and CpG11– 12) (Figure 1A).
We quantified DNA methylation at the 12 CpGs in 3 carti-
lage sample types: OA knee, OA hip, and femoral neck fracture 
(non- OA controls). In all samples, DNA methylation was stratified 
by rs11583641 genotype (Figure 1B). Significant methylation 
QTLs were identified at 3 of 12 CpGs: CpG8 (P < 0.0001), CpG9 
(cg18131582) (P = 0.014), and CpG10 (P < 0.001). This defined 
the limits of the differentially methylated region in arthroplasty car-
tilage to a 210- bp region. At the 3 CpGs, the effect allele, C, of 
rs11583641 was associated with lower levels of DNA methyla-
tion as compared to that in the presence of the non- risk allele, T 
(Figure 1B).
We analyzed median DNA methylation levels across the 
region (Figure 1C). At 8 of 12 CpGs, DNA was hypermethylated 
(median >75%). At CpGs 8– 10 the median DNA methylation level 
was lower (20.3– 54.5%), while interindividual variability was high 
(64% DNA methylation range at CpG8). This provides further evi-
dence for the regulatory function of the CpG cluster, specifically 
the 210- bp differentially methylated region.
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Impact of joint site and disease state on DNA meth-
ylation. We investigated the effect of the joint site on DNA meth-
ylation in OA. At 8 of 12 CpGs, DNA methylation levels were 
significantly lower (P < 0.05) in hip cartilage (n = 33– 43) than in 
knee cartilage (n = 44– 55) (Figure 2A).
Next, we tested for a disease- specific effect on DNA methyl-
ation in hip samples. At 6 of 12 CpGs, higher median DNA meth-
ylation levels were measured in femoral neck fracture samples 
(n = 20– 27) compared to OA hip samples (P < 0.01) (Figure 2A). The 
greatest differences between median values (12.0% and 12.5%, 
respectively) were observed at CpG6 (P = 4.5 × 10– 13) and CpG9 
(P = 8.5 × 10– 8). The exception to this trend was CpG12, the most 
distal from the cluster, at which femoral neck fracture DNA methyl-
ation was lower (P = 9.2 × 10– 5) than in OA hip samples (Figure 2A).
We stratified DNA methylation data from sample type groups 
by rs11586341 genotype (Figure 2B). We used a linear regression 
analysis to calculate the percentage contribution of genotype to 
differences in DNA methylation in each of the 4 groups: all OA (hip 
and knee), OA knee, OA hip, and femoral neck fracture. Within 
the 210- bp differentially methylated region, the strongest effect 
was measured at CpG8 in all sample types, and the greatest 
ge notype effect was seen in OA knee samples (76.9%) (Figure 2B). 
Indeed, the effect was stronger in knee cartilage than hip cartilage 
at all 3 differentially methylated region CpGs (Figure 2B). At CpG8 
and CpG10, the genotype effects were significantly greater in all 
OA disease groups compared to femoral neck fracture controls 
(for CpG8, 63.3– 76.9% in OA groups versus 44.5% in controls; 
for CpG10, 36.0– 41.4% in OA groups versus 8.9% in controls). 
Figure 1. Cartilage methylation quantitative trait locus analysis of 12 CpG sites within the putative COLGALT2 enhancer. A, A schematic 
representation of chromosome 1 shows the location of the COLGALT2 gene at 1q25.3 (arrow). The osteoarthritis- associated single- nucleotide 
polymorphism rs11583641 within the 3′- untranslated region of COLGALT2 and the putative intronic enhancer region containing cg18131582 
are shown. The locations of the 12 investigated CpGs are indicated. Circles represent CpGs (CpGs 1– 12); cg18131582 is CpG9 (green circle). 
B, Violin plots show DNA methylation values in arthroplasty cartilage samples (n = 102– 128) at the 12 investigated CpGs, stratified by genotype 
at rs11583641. P values were calculated by Kruskal- Wallis nonparametric test. C, DNA methylation levels were measured in all arthroplasty 
cartilage samples (n = 102– 128) at each of the 12 CpGs across the enhancer, plotted irrespective of genotype. In B and C, solid and dashed 



























































































CpG 1 CpG 2 CpG 3 CpG 4
P=0.105, n=113 P=0.496, n=117 P=0.418, n=111
P<0.0001, n=117
CpG 5 CpG 6 CpG 7 CpG 8
CC CT TT CC CT TT CC CT TT CC CT TT
CC CT TT CC CT TT CC CT TT CC CT TT
CC CT TT CC CT TT CC CT TT CC CT TT
P=0.014, n=128 P<0.0001, n=117 P=0.324, n=104 P=0.296, n=105
CpG 9 CpG 10 CpG 11 CpG 12




COLGALT2 IN OA |      5
Interestingly, at CpG9, the genotype effect was greatest in femoral 
neck fracture samples (33.3%) (Figure 2B).
Role of the region as a COLGALT2 enhancer. We next 
tested the region for regulatory activity using a reporter gene assay. 
For this assay, and for subsequent investigations reported in this 
study, we chose to focus on the 8 CpGs within the cg18131582 
cluster. A 503- bp region encompassing CpGs 3– 10 was cloned 
into a Lucia reporter gene vector (Figure 3A). The cloned region 
also contained 2 SNPs, rs943409 (G>A) and rs734657 (C>A), the 
latter of which is in high linkage disequilibrium with rs11583641 
(r2 = 0.83 for the British in England and Scotland population) 
(Figure 3B). Genotypes at rs943409 and rs734657 naturally occur 
in 3 haplotypes: G_C, A_C, and G_A. All 3 haplotypes were tested 
for their impact on enhancer activity.
Two of the three constructs had increased enhancer activ-
ity (P < 0.001) in Tc28a2 chondrocytes (Figure 3B). Both of 
these haplotypes contained the rs734657 C allele (G_C and 
A_C) and both showed a level of enhancer activity that was 
3.1– 4.1- fold above that of the control construct. No signifi-
cant difference (P > 0.05) was observed between the activity 
of these 2 constructs (Figure 3B). The G_A haplotype con-
ferred significantly lower activity (P < 0.001) (Figure 3B), indi-
cating that the rs734757 genotype impacts enhancer function, 
whereby the C allele (corresponding to the OA effect allele, C, 
at rs11583641) increases the enhancer activity of the region. 
We found no evidence that the rs943409 genotype influenced 
activity. Methylation of the enhancer region significantly reduced 
the enhancer activity of all 3 haplotype constructs (P < 0.05) 
(Figure 3B, middle panel).
Next, we investigated the gene target of the enhancer in 
cartilage. Using CRISPR- Cas9 and paired gRNAs targeting 
upstream and downstream of the region, we deleted 483 bp of 
the Tc28a2 genome, encompassing CpGs 3– 10 (Figure 3A). The 
deletion resulted in a 2.7- fold reduction in COLGALT2 expres-
sion (P = 0.004) (Figure 3C). No significant difference (P > 0.16) 
in the expression of RGL1 or TSEN15, which flank COLGALT2, 
was detected (Figure 3C). To ensure that the intronic deletion did 
not affect COLGALT2 splicing, PCR amplification of cDNA from 
control and deletion cells was performed using primers spanning 
the deletion. No aberrant splicing was observed (Supplementary 
Figure 2A, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/ abstract). 
These results confirm that COLGALT2 is a gene target of the 
enhancer in chondrocytes.
Previous studies have demonstrated compensatory expres-
sion of COLGALT1 following COLGALT2 knockdown in U2OS 
cells (23). In Tc28a2 cells, no subsequent change in COLGALT1 
expression was observed following deletion of the COLGALT2 
enhancer (Supplementary Figure 2B, available on the Arthri-
tis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41738/ abstract).
Figure 2. Effects of joint site and disease status on DNA methylation. A, DNA methylation levels at the 12 investigated CpGs in cartilage 
samples from patients with knee osteoarthritis (OA) (n = 47– 60), hip OA (n = 33– 44), or femoral neck fracture (NOF) (n = 20– 27). Solid and 
dashed horizontal lines represent the median and interquartile range. * = P < 0.05; ** = P < 0.01; **** = P < 0.0001, calculated by Mann- Whitney 
test. B, Heatmap showing the influence of the rs11583641 genotype on DNA methylation levels at the 12 CpGs in cartilage samples from 
patients with all OA (both hip and knee; n = 79– 92), knee OA (n = 44– 55), hip OA (n = 33– 43), or femoral neck fracture (n = 20– 27). Values (r2) 
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Regulation of COLGALT2 expression by enhancer 
methylation. Next, we investigated whether enhancer 
DNA methylation impacts COLGALT2 expression. We used 
dCas9 modulators of CpG methylation in Tc28a2 chondrocytes: 
dCas9- DNMT3a (to methylate the CpGs) or dCas9- TET1 (to 
demethylate the CpGs). Six gRNAs (gRNA3– 8) were designed, 
which tiled across the region to target the enhancer CpGs 
(Figure 4A). We expressed individual gRNAs in cells along with the 
dCas9 constructs.
Coexpression of dCas9- DNMT3a and gRNAs successfully 
increased DNA methylation at the CpGs (Figure 4B). The great-
est increases in DNA methylation levels were reached at CpG8, 
CpG9, and CpG10, at which distinct gRNAs increased meth-
ylation by up to 38.0%, 37.5%, and 23.0%, respectively (Sup-
plementary Figure 3, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/ 
abstract). No further increase in DNA methylation level was 
reached by expression of multiple gRNAs (Supplementary 
Figure 4A, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/abstract). 
A significant reduction in COLGALT2 (P < 0.01) was measured 
following coexpression of dCas9- DNMT3a with gRNA3 (0.58- 
fold decrease), gRNA4 (0.56- fold decrease), gRNA6 (0.68- fold 
decrease), or gRNA8 (0.62- fold decrease) (Figure 4B). These 4 
gRNAs all edited DNA methylation at CpG8– 10 (Supplementary 
Figure 3, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41738/ abstract). 
Of note, increasing DNA methylation at CpG9 and CpG10 alone 
(gRNA7) did not significantly decrease expression of COLGALT2 
(Figure 4B). In all instances, there were no significant changes 
(P > 0.05) in the expression of RGL1 and TSEN15 (Supplemen-
tary Figure 4B).
A reduction in enhancer DNA methylation was achieved 
using  dCas9- TET1 (Figure 4C). Decreasing DNA methylation 
resulted in an increase in COLGALT2 expression (Figure 4C). As 
above, significant changes in gene expression resulted when 
gRNAs 3, 4, 6, and 8 were expressed in the cells. The mean 
DNA methylation levels at CpG8, CpG9, and CpG10 were 
reduced by up to 11.8% (with gRNA6), 19.2% (with gRNA4), 
and 18.7% (with gRNA6), respectively (Supplementary Figure 3, 
available on the Arthritis & Rheumatology website at http://onlin e  
libr ary.wiley.com/doi/10.1002/art.41738/ abstract). As previously 
Figure 3. Effect of DNA methylation at the CpG cluster and investigation of enhancer activity in the region. A, A schematic representation of 
the location of COLGALT2, RGL1, and TSEN15. Circles represent the 8 CpGs (CpGs 3– 10) that were captured; cg18131582 is CpG9 (green 
circle). Vertical lines represent the genomic positions of the 2 enhancer single- nucleotide polymorphisms (SNPs). Positions of the guide RNAs 
(1 and 2) used for the deletion of the region are indicated by arrows. B, Lucia reporter assays assessing enhancer activity in chondrocytes in 
the presence of constructs containing the 3 haplotypes of rs943409 and rs734657 (left) and the 3 haplotypes in a methylated or unmethylated 
state (middle); values were normalized to those in an empty vector control. Symbols represent individual samples (n = 7 per group); bars show 
the mean ± SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001, by Kruskal- Wallis test with Dunn’s test for correction (left 
panel) or by multiple t- tests with the Holm- Sidak test for correction (middle panel). Linkage disequilibrium (r2) values between rs11583641 and 
the enhancer SNPs rs943409 and rs734657 in the British in England and Scotland population are shown (right). C, RGL1, COLGALT2, and 
TSEN15 gene expression following deletion of the enhancer in chondrocytes; values were normalized to those measured in control (unedited) 
cells. P values were calculated by paired t- test (n = 6).
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observed, modulation of DNA methylation levels did not lead to 
significant changes in RGL1 or TSEN15 expression (Supplemen-
tary Figure 4B).
In both experiments, targeted changes in DNA methylation at 
CpG8 and CpG10 resulted in changes in COLGALT2 expression. 
These results complement the observations made using patient 
samples and confirm the importance of the methylation status of 
CpG8 and CpG10 in the regulatory function of the enhancer.
Correlation of the genotype at rs11583641 with 
COLGALT2 expression. Finally, we returned our attention to the 
hip or knee cartilage samples from human patients in order to 
investigate the effect of the genotype at rs11583641 on allelic 
expression of COLGALT2. Allelic expression imbalance analysis 
revealed an imbalance between the C and T transcripts of COL-
GALT2 in heterozygous patients (Figure 5A). A 1.94- fold mean 
increase (P < 0.0001) in expression of the OA effect allele, C, 
Figure 4. Epigenetic modulation of the enhancer in Tc28a2 cells. A, Schematic diagram showing the genomic position of the 6 guide RNAs 
(gRNAs) used for modulating the epigenome (gRNAs 3– 8), relative to the 8 CpGs; cg18131582 is CpG9 (green circle). B, Left, DNA methylation 
levels at the 8 CpGs in Tc28a2 chondrocytes following expression of DNA methyltransferase 3a (DNMT3a)– dead Cas9 (dCas9) protein in 
controls (no gRNA) or in samples with a targeting gRNA (n = 3). Right, COLGALT2 expression in chondrocytes following editing of DNA 
methylation with gRNAs. Values were normalized to the mean values in no-gRNA control cells (each n = 3). C, Left, DNA methylation levels at 
the 8 CpGs in Tc28a2 chondrocytes following expression of dCas9- TET1 protein in controls or in samples with a targeting gRNA (n = 3). Right, 
COLGALT2 expression in control cells following editing of DNA methylation with gRNAs. Values were normalized to the mean values in no-gRNA 
control cells (each n = 3). In B and C, * = P < 0.05; ** = P < 0.01; *** = P < 0.001, by a 1- tailed paired t- test.
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was observed. Interestingly, an allelic expression imbalance was 
detected in 13 of 27 samples used for the analysis, yet in the 
remaining 14 samples no imbalance was found (Figure 5A). This 
observation could not be explained by sex, age, disease, or joint 
differences between the patients.
In the cartilage samples that showed significant allelic 
expression imbalance, allelic ratios correlated with DNA 
methylation at the enhancer CpGs (Figure 5B). Significant cor-
relations marking methylation-expression QTLs were discov-
ered at CpG4, CpG8, and CpG9 (P = 0.036, P = 0.019, and 
P = 0.036, respectively), and a trend was emerging at CpG7 
(P = 0.057) (Figure 5B), supporting OA- associated regulation 
of COLGALT2, mediated by genetic and epigenetic interplay in 
cartilage.
DISCUSSION
The GWAS era has spanned more than a decade and has 
resulted in the identification of >90 independent OA genetic asso-
ciation signals. However, it has proven challenging to biologically 
interpret these results and translate genetic discoveries into effec-
tive therapies (22). Consequently, epigenetic data sets are increas-
ingly being applied post- GWAS to prioritize causal genes and 
their regulatory elements for focused analysis (10,11,18,20). In the 
current study, we performed a focused analysis of one such risk 
locus, on chromosome 1, at which intronic DNA methylation has 
previously been correlated with OA genetic risk (20). We applied a 
broad range of molecular biology tools in cartilage samples and in 
a chondrocyte cell model, to characterize the genetic and epige-
netic factors regulating gene expression at the locus.
In patient arthroplasty samples, we analyzed DNA methyla-
tion at 12 CpGs and defined the differentially methylated region 
as spanning 210 bp and containing 3 CpGs (CpGs 8– 10). The 
rs11583641 effect allele, C, corresponded to a reduction in 
DNA methylation levels compared to levels in the non- effect 
allele, T. At the 3 CpGs, the strongest effect size was observed 
in knee cartilage. Allelic expression imbalance analysis confirmed 
that the OA effect allele of rs11583641 correlated with increased 
expression of COLGALT2. Furthermore, correlations between 
allelic expression imbalance ratios and DNA methylation revealed 
a methylation-expression QTL.
The region was shown to have regulatory function in vitro, 
which was significantly hindered by DNA methylation. We identi-
fied a genetic influence on enhancer function, whereby the major 
allele of rs734657, located within the enhancer and correspond-
ing to the effect allele at rs11583641, resulted in increased Lucia 
Figure 5. Allelic expression imbalance (AEI) analysis of rs11583641 and COLGALT2. A, Left, Allelic (C/T) ratios in cartilage samples from 
osteoarthritis (OA) patients heterozygous for rs11583641 (n = 27). In each sample, the ratio of values for cDNA and DNA between the C (OA 
effect) allele and T allele was plotted; each symbol represents 1 of 3 technical repeats. Right, Mean DNA and cDNA values in the presence of 
the C allele versus the T allele in heterozygous patients. Values are shown as box plots, with the line inside the box representing the median, 
boxes showing the interquartile range, and whiskers showing the minimum and maximum values. **** = P < 0.0001 by Wilcoxon’s matched 
pairs signed rank test (1- tailed). B, Allelic ratios (log2) of COLGALT2 plotted against matched DNA methylation level values at CpGs 3– 10 (n = 































































































































































































































































CpG 3 CpG 4 CpG 5 CpG 6




COLGALT2 IN OA |      9
expression. These in vitro findings demonstrate a synergistic rela-
tionship between genetic and epigenetic factors in the regulation 
of gene expression. The effect allele at OA- associated SNPs cor-
relates with an increase in gene expression.
The advent of CRISPR- Cas9 and subsequent develop-
ment of the Cas9 toolbox has revolutionized targeted editing of 
the genome and epigenome (29). CRISPR- Cas9 deletion of the 
enhancer confirmed that COLGALT2 was a target gene, while 
gene expression of RGL1 and TSEN15, which flank  COLGALT2, 
remained unchanged. The development of a catalytically dead 
Cas9 fused to enzymes that either methylate (DNMT3a) or 
demethylate (TET1) CpGs has provided an elegant tool for preci-
sion editing of DNA methylation (30). Here, we have applied this 
technology in human immortalized chondrocytes and demon-
strated a causal relationship between DNA methylation and 
COLGALT2 expression. Concordant with the measurements of 
DNA methylation and gene expression in cartilage samples, a 
reduction in DNA methylation resulted in increased COLGALT2 
expression. Furthermore, the results of this investigation con-
firmed that the 3 differentially methylated region CpGs, particularly 
CpG8 and CpG10, are the functional mediators.
COLGALT2 is a compelling candidate gene in the etiol-
ogy of OA. Collagens are a major constituent of the extracellu-
lar matrix of articular cartilage, the central tissue in OA pathology. 
Two enzymes are required for collagen glycosylation: procollagen 
galactosyltransferase 1 and 2, which are encoded by COLGALT1 
and COLGALT2, respectively. COLGALT1 mutations cause the 
collagen deficiency condition known as cerebral small vessel 
disease (31), and a recent genetic investigation identified a rare 
coding variant in COLGALT1 as a potential cause of erosive hand 
OA (32). Polymorphisms in COLGALT2 have been associated with 
height, body fat distribution, and schizophrenia (33– 35), in addi-
tion to OA (11). The many associations between the disruption 
of collagen posttranslational modification and diseases, including 
osteogenesis imperfecta and Bruck syndrome, provide evidence 
that aberrant posttranslational modification can be detrimental to 
cartilage integrity (36– 38).
Taking into consideration all our observations in both anal-
yses of human tissue and in vitro cartilage models, we propose 
the following model: the OA effect allele marked by the SNP 
rs11583641 mediates decreased cartilage DNA methylation at 
the COLGALT2 enhancer, resulting in increased expression of the 
gene and a subsequent increase in galactosyltransferase activity. 
We hypothesize that resulting over- modification of the collagen tri-
ple helix could detrimentally affect the structural or mechanotrans-
ducive properties of articular cartilage, contributing to OA. This 
requires further investigation.
Using novel epigenome modulating tools, we established 
a causal relationship between enhancer DNA methylation and 
COLGALT2 expression. The absence of COLGALT2 allelic 
expression imbalance in a proportion of the heterozygous 
patients in the study, along with the evidence that the genotype 
at rs734657 contributes to regulatory function, indicates that the 
genotype at multiple SNPs in the region could function in concert 
to finely tune COLGALT2 expression. This also requires further 
investigation.
Our understanding of the interplay between genetics and epi-
genetics in OA is rapidly developing (16). The discovery of a role 
for epigenetics in musculoskeletal diseases exposes the human 
epigenome as an exploitable pharmacologic target. To enable 
this, complete knowledge of the molecular mechanisms under-
pinning pathogenic subtypes is required. A precision medicine 
approach to treat musculoskeletal disorders requires a deeper 
understanding of the relationship between genetics and disease, 
as well as stratification of patients based on the underlying biol-
ogy (39). In OA, there is increasing evidence for different molecular 
pathways underlying disease subtypes, ultimately presenting with 
the same endotype but requiring distinct therapeutic approaches 
(40,41). The identification of OA risk genes, such as COLGALT2, 
provides scope for novel pharmacologic interventions within 
patient subgroups.
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